NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Juventas Cell Therapy Ltd.

Juventas Cell Therapy Ltd.

Private
TianjinHealthcare & Life Scienceshttp://www.juventas.cn/

Last Round

Series C

Oct 25, 2021

Est. Valuation

$263.04M

Total Funding Raised

$232.3M

Company Overview

Juventas Cell Therapy Ltd. is a biotechnology company that develops and manufactures innovative immune cell and gene therapies for the treatment of hematological malignancies and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapycell therapygene therapybiopharmaceuticalimmunotherapyautologous cell therapyallogeneic cell therapyinduced pluripotent stem cellsiPSCgene-editinghematologic malignanciesblood cancer treatmentprecision medicineGMP manufacturingbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Juventas Cell Therapy Ltd. Comps

Public and private peers based on sector, stage, and business model.

Juventas Cell Therapy Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Juventas Cell Therapy Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 25, 2021
Series CJul 12, 2021
Series BNov 19, 2020
Series A ExtensionJul 9, 2019
Series ADec 17, 2018

Key People

Founding team and executive leadership

James Wang

Chief Technology Officer (CTO)

Executive Team

Juventas Cell Therapy Ltd. Investors

Notable investors and investment history

Juventas Cell Therapy Ltd. investors
InvestorRounds
Emerging Technology PartnersSeries B
CCIC CapitalSeries C
China International Capital CorporationSeries C
Dalton VentureSeries A, Series A Extension
Tianjin Venture Capital Management Co., Ltd.Series C, Series B
Oceanpine CapitalSeries C
Delian CapitalSeries C

Juventas Cell Therapy Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Juventas Cell Therapy Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Juventas Cell Therapy Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTianjin
Employee Range32
Year Founded2018
Last FundingOct 25, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.